Cancer vaccine HSPPC-96 next generationAlternative Names: Next generation Oncophage®; Next generation vitespen; Oncophage NexGen; Vitespen NexGen
Latest Information Update: 04 Sep 2006
At a glance
- Originator Antigenics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Sep 2006 Discontinued - Preclinical for Cancer in USA (Injection)
- 17 Jun 2003 Preclinical trials in Cancer in USA (Injection)